Cargando…

Bioelectrical impedance phase angle as a prognostic indicator in breast cancer

BACKGROUND: Bioelectrical impedance analysis (BIA) is an easy-to-use, non-invasive, and reproducible technique to evaluate changes in body composition and nutritional status. Phase angle, determined by bioelectrical impedance analysis (BIA), detects changes in tissue electrical properties and has be...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Digant, Lammersfeld, Carolyn A, Vashi, Pankaj G, King, Jessica, Dahlk, Sadie L, Grutsch, James F, Lis, Christopher G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527613/
https://www.ncbi.nlm.nih.gov/pubmed/18727837
http://dx.doi.org/10.1186/1471-2407-8-249
_version_ 1782158825270280192
author Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
King, Jessica
Dahlk, Sadie L
Grutsch, James F
Lis, Christopher G
author_facet Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
King, Jessica
Dahlk, Sadie L
Grutsch, James F
Lis, Christopher G
author_sort Gupta, Digant
collection PubMed
description BACKGROUND: Bioelectrical impedance analysis (BIA) is an easy-to-use, non-invasive, and reproducible technique to evaluate changes in body composition and nutritional status. Phase angle, determined by bioelectrical impedance analysis (BIA), detects changes in tissue electrical properties and has been hypothesized to be a marker of malnutrition. Since malnutrition can be found in patients with breast cancer, we investigated the prognostic role of phase angle in breast cancer. METHODS: We evaluated a case series of 259 histologically confirmed breast cancer patients treated at Cancer Treatment Centers of America. Kaplan Meier method was used to calculate survival. Cox proportional hazard models were constructed to evaluate the prognostic effect of phase angle independent of stage at diagnosis and prior treatment history. Survival was calculated as the time interval between the date of first patient visit to the hospital and the date of death from any cause or date of last contact/last known to be alive. RESULTS: Of 259 patients, 81 were newly diagnosed at our hospital while 178 had received prior treatment elsewhere. 56 had stage I disease at diagnosis, 110 had stage II, 46 had stage III and 34 had stage IV. The median age at diagnosis was 49 years (range 25 – 74 years). The median phase angle score was 5.6 (range = 1.5 – 8.9). Patients with phase angle <= 5.6 had a median survival of 23.1 months (95% CI: 14.2 to 31.9; n = 129), while those > 5.6 had 49.9 months (95% CI: 35.6 to 77.8; n = 130); the difference being statistically significant (p = 0.031). Multivariate Cox modeling, after adjusting for stage at diagnosis and prior treatment history found that every one unit increase in phase angle score was associated with a relative risk of 0.82 (95% CI: 0.68 to 0.99, P = 0.041). Stage at diagnosis (p = 0.006) and prior treatment history (p = 0.001) were also predictive of survival independent of each other and phase angle. CONCLUSION: This study demonstrates that BIA-derived phase angle is an independent prognostic indicator in patients with breast cancer. Nutritional interventions targeted at improving phase angle could potentially lead to an improved survival in patients with breast cancer.
format Text
id pubmed-2527613
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25276132008-09-02 Bioelectrical impedance phase angle as a prognostic indicator in breast cancer Gupta, Digant Lammersfeld, Carolyn A Vashi, Pankaj G King, Jessica Dahlk, Sadie L Grutsch, James F Lis, Christopher G BMC Cancer Research Article BACKGROUND: Bioelectrical impedance analysis (BIA) is an easy-to-use, non-invasive, and reproducible technique to evaluate changes in body composition and nutritional status. Phase angle, determined by bioelectrical impedance analysis (BIA), detects changes in tissue electrical properties and has been hypothesized to be a marker of malnutrition. Since malnutrition can be found in patients with breast cancer, we investigated the prognostic role of phase angle in breast cancer. METHODS: We evaluated a case series of 259 histologically confirmed breast cancer patients treated at Cancer Treatment Centers of America. Kaplan Meier method was used to calculate survival. Cox proportional hazard models were constructed to evaluate the prognostic effect of phase angle independent of stage at diagnosis and prior treatment history. Survival was calculated as the time interval between the date of first patient visit to the hospital and the date of death from any cause or date of last contact/last known to be alive. RESULTS: Of 259 patients, 81 were newly diagnosed at our hospital while 178 had received prior treatment elsewhere. 56 had stage I disease at diagnosis, 110 had stage II, 46 had stage III and 34 had stage IV. The median age at diagnosis was 49 years (range 25 – 74 years). The median phase angle score was 5.6 (range = 1.5 – 8.9). Patients with phase angle <= 5.6 had a median survival of 23.1 months (95% CI: 14.2 to 31.9; n = 129), while those > 5.6 had 49.9 months (95% CI: 35.6 to 77.8; n = 130); the difference being statistically significant (p = 0.031). Multivariate Cox modeling, after adjusting for stage at diagnosis and prior treatment history found that every one unit increase in phase angle score was associated with a relative risk of 0.82 (95% CI: 0.68 to 0.99, P = 0.041). Stage at diagnosis (p = 0.006) and prior treatment history (p = 0.001) were also predictive of survival independent of each other and phase angle. CONCLUSION: This study demonstrates that BIA-derived phase angle is an independent prognostic indicator in patients with breast cancer. Nutritional interventions targeted at improving phase angle could potentially lead to an improved survival in patients with breast cancer. BioMed Central 2008-08-27 /pmc/articles/PMC2527613/ /pubmed/18727837 http://dx.doi.org/10.1186/1471-2407-8-249 Text en Copyright © 2008 Gupta et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gupta, Digant
Lammersfeld, Carolyn A
Vashi, Pankaj G
King, Jessica
Dahlk, Sadie L
Grutsch, James F
Lis, Christopher G
Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title_full Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title_fullStr Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title_full_unstemmed Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title_short Bioelectrical impedance phase angle as a prognostic indicator in breast cancer
title_sort bioelectrical impedance phase angle as a prognostic indicator in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527613/
https://www.ncbi.nlm.nih.gov/pubmed/18727837
http://dx.doi.org/10.1186/1471-2407-8-249
work_keys_str_mv AT guptadigant bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT lammersfeldcarolyna bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT vashipankajg bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT kingjessica bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT dahlksadiel bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT grutschjamesf bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer
AT lischristopherg bioelectricalimpedancephaseangleasaprognosticindicatorinbreastcancer